Verily and Samsung announced a partnership to integrate Galaxy smartwatch sensor data into Verily’s Pre platform to support clinical trials. The collaboration aims to create an end‑to‑end system for deploying wearables, collecting and analyzing remote patient data, and interpreting results for sponsors and contract research organizations. The integration targets streamlined device provisioning, data standardization, and validated endpoints derived from continuous physiologic monitoring. Verily emphasized that the move will reduce operational friction for trials that use consumer wearables while preserving data quality standards needed for regulatory submissions. Pharmaceutical sponsors testing digital endpoints or decentralized trial designs may adopt the combined offering to accelerate recruitment, improve retention, and gain richer longitudinal measurements.